Guardian Pharmacy Services, Inc. Stock Price, News & Analysis

Guardian Pharmacy Services (NYSE: GRDN) filed a Form S-3 shelf registration on October 14, 2025 to permit the issuance of up to 1,020,000 new Class A shares and the potential resale of up to 4,980,000 outstanding Class A shares by selling stockholders.

Guardian said neither it nor the selling stockholders have immediate plans to sell under the shelf. The filing is not yet effective. Guardian also executed lock-up agreements covering approximately 17,188,059 shares and the automatic conversion of 12,759,054 Class B shares on March 28, 2026, restricting sales through June 30, 2026. As of September 30, 2025, there were 36,253,744 Class A shares outstanding.

Guardian Pharmacy Services (NYSE: GRDN) will report third quarter 2025 financial results on Monday, November 10, 2025 after market close. A conference call to review results is scheduled for 4:30 PM ET on the same day.

Investors can listen via audio webcast at https://investors.guardianpharmacy.com or dial (646) 564-2877 (U.S.) or +1 (800) 549-8228 (international) using conference ID 11965. A replay will be available shortly after the call and remain accessible for approximately 60 days.

Guardian Pharmacy Services (NYSE:GRDN) announced its participation in the upcoming Jefferies Healthcare Services Conference in Nashville, TN, on September 30, 2025. CEO Fred Burke will participate in a fireside chat with Jefferies analyst Brian Tanquilut at 3:35 p.m. CT (4:35 p.m. ET).

The company will host investor meetings during the conference. A live audio webcast will be available on the company's investor relations website, with a replay accessible for 90 days following the event.

Guardian Pharmacy Services (NYSE:GRDN) reported strong Q2 2025 financial results, with revenue increasing 15% year-over-year to $344.3 million. The company's resident count grew 12% to over 195,000, while Adjusted EBITDA reached $25.0 million.

The company expanded its footprint through strategic acquisitions in Wichita, KS and Seattle, WA, launched a new greenfield pharmacy in Naples, FL, and subsequently acquired Managed Healthcare Pharmacy in Oregon. Guardian also completed a non-dilutive secondary offering of 8.625 million shares, enhancing trading liquidity.

Based on strong H1 2025 performance, Guardian raised its full-year guidance, projecting revenue of $1.39-1.41 billion (up from $1.33-1.35 billion) and Adjusted EBITDA of $100.0-102.0 million (up from $97.0-101.0 million).

Guardian Pharmacy Services (NYSE:GRDN) has announced the acquisition of Managed Healthcare Pharmacy, a leading long-term care (LTC) pharmacy in Oregon. The strategic acquisition marks Guardian's first physical presence in Oregon and expands its Pacific Northwest footprint.

Managed Healthcare Pharmacy, established in 1991, operates in Eugene and Medford, serving assisted living facilities, behavioral health communities, and individuals with intellectual and developmental disabilities across Oregon and Washington. The existing leadership and staff will be retained, and the pharmacy will maintain its current name while benefiting from Guardian's centralized corporate support in areas including data analytics, HR, IT, and payor relations.

Guardian Pharmacy Services (NYSE:GRDN) has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close. The company will host a conference call at 4:30 PM ET to discuss the results.

Investors can access the conference call through an audio webcast on the company's investor relations website or by dialing (646) 564-2877 (U.S.) or +1 (800) 549-8228 (international) with conference ID "95006". A replay will be available for approximately 60 days following the call.

Guardian Pharmacy Services (NYSE: GRDN) announced the merger and relocation of Winyah Pharmacy and Preferred Care into a new state-of-the-art headquarters in Charleston, South Carolina, operating under Guardian Pharmacy of South Carolina. The new facility is nearly double the size of previous locations combined and features advanced automation systems, robotic dispensing machines, and an IV infusion therapy suite. The consolidation brings all employees under one roof and positions the company for expanded services and growth. As part of Guardian Pharmacy Services' network of over 50 pharmacies serving 7,000 LTC facilities nationwide, the local team focuses on customer service while benefiting from Guardian's centralized corporate support for functions like analytics, HR, and IT. The company plans additional hiring throughout the year to support its growth trajectory.

Guardian Pharmacy Services (NYSE: GRDN) has acquired Mercury Pharmacy Services, a leading long-term care (LTC) pharmacy in Mountlake Terrace, Washington. This strategic acquisition marks Guardian's first entry into Washington state and the Pacific Northwest region. Mercury Pharmacy Services, founded in 2001, is a major LTC pharmacy provider in the Seattle-Tacoma area, serving assisted living, skilled nursing, behavioral health communities, and individuals with developmental disabilities. The existing Mercury team will remain in place, operating under the same name. Guardian's business model allows local pharmacy teams to focus on customer service while its Corporate Support Team handles backend operations. Founded in 2004, Guardian has grown to over 50 pharmacies serving approximately 7,000 LTC facilities nationwide through organic growth and acquisitions.

Guardian Pharmacy Services (NYSE: GRDN) has announced the pricing of its underwritten public offering of 7.5 million shares of Class A common stock at $21.00 per share. The offering consists of 6,059,553 shares from selling stockholders and 1,440,447 shares from Guardian in a non-dilutive synthetic secondary transaction. The underwriters have a 30-day option to purchase an additional 1,125,000 shares.

The offering, expected to close on May 27, 2025, is structured as non-dilutive since Guardian will use all net proceeds to repurchase 1,440,447 shares of Class A common stock at the offering price less underwriting discount. The total number of outstanding shares will remain unchanged after completion. Raymond James leads the offering as bookrunning manager, with Stephens Inc. and Truist Securities as joint bookrunning managers.